Cell & Gene Therapy approaches at GlaxoSmithKline
Unfortunately this School Seminar is cancelled until further notice. If possible we will try to reschedule later this term.
Speaker: Dr Takis Athanasopoulos, Head of Transgene Delivery, GlaxoSmithKline (GSK), Medicines Research Centre
Cell & Gene Therapy approaches at GlaxoSmithKline: From Discovery Research to Manufacturing and Commercialisation
Gene therapy, genome editing and stem cells are areas of advance medical research in which we are increasingly seeing breakthroughs tacking a diversity of diseases, such as cancer, blindness, immune dysfunction, dementia and neurodegeneration, HIV/AIDS, heart and lung disease, skin disorders, and a plethora of inherited illnesses like haemophilia, cystic fibrosis, muscular dystrophy and immunodeficiency. Dr Athanasopoulos is an alumni PhD graduate of RHUL Bioscience, and now a Research Director in the gene therapy field at GSK (GlaxoSmithKline), a leading UK and global pharmaceutical company. He will provide insights and examples of the industrial processes from “bench to bedside” in the translation of gene and stem cell therapy into clinical practice, and the use of virus-like structures to deliver genetic material into patient cells.